Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe study record history now includes a new revision entry v3.6.6, replacing the previous v3.6.5 in the version list. This reflects an updated release note for the record.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page’s revision label in the Record History updates from v3.6.4 to v3.6.5.SummaryDifference0.1%

- Check51 days agoChange DetectedA new revision entry was added to the study record history, updating the version from v3.6.3 to v3.6.4. This change appears to be an administrative update to the page rather than a modification to the trial data or content.SummaryDifference0.1%

- Check73 days agoChange DetectedA new revision entry 'Revision: v3.6.3' was added to the Record History, replacing the previous 'Revision: v3.6.2'. This reflects a newer system release for the page history.SummaryDifference0.1%

- Check80 days agoChange DetectedA new revision entry labeled v3.6.2 was added to the history and the previous revision v3.6.0 was removed from the visible history, updating the record of the study's release notes.SummaryDifference0.1%

- Check94 days agoChange DetectedUpdates to the study record history page include a new Revision: v3.6.0 and removal of the previous v3.5.5 label. In addition, the page now presents a 'Check who can join' option and a 'Find Contact Information' link to assist potential participants in assessing eligibility and contacting the study team.SummaryDifference0.5%

Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.